Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03233438 · ClinicalTrials.gov registry record · Phase 4
Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 91
- Enrollment target
NCT03233438 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 91 participants.
The verdict
NCT03233438, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 91 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of a new critical pathway (use of guideline-based patient identification criteria and for those who meet these criteria, use of dalbavancin) compared to usual care for the treatment of ABSSI (Acute Bacterial Skin and Skin Structure Infections)
Interventions
- DRUG Dalbavancin
- DRUG Usual Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2017-07-24 |
| Est. Completion | 2018-10-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03233438
The ClinicalTrials.gov registry entry for NCT03233438 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dalbavancin is the first listed.
NCT03233438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03233438 about?
NCT03233438 is a clinical study titled "Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)". The purpose of this study is to assess the effect of a new critical pathway (use of guideline-based patient identification criteria and for those who meet these criteria, use of dalbavancin) compared to usual care for the treatment of ABSSI (Acute Bacterial Skin and Skin Structure Infections)
What is the current status of trial NCT03233438?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 91 participants. The study started on 2017-07-24. Estimated completion is 2018-10-30.
What interventions are being tested in trial NCT03233438?
The interventions under investigation include: Dalbavancin (DRUG), Usual Care (DRUG).
Who is sponsoring clinical trial NCT03233438?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.